MY PICK IS ELN

[kingofthehill]

ELN


For the nine months ended 9/30/03, revenues fell 45% to $673.3M. Net loss from continuing operations decreased 87% to $211.4 million. Revenues reflect the genericization of Zanaflex. Lower loss reflects a decrease in investment losses.

[kingofthehill]

ELN is on fire !!!

19-Dec-03 6.37 6.70 6.32 6.62 5,979,300 6.62
18-Dec-03 6.44 6.53 6.33 6.44 2,810,300 6.44
17-Dec-03 6.15 6.50 6.03 6.44 6,439,600 6.44
16-Dec-03 5.97 6.15 5.80 6.15 4,972,000 6.15
15-Dec-03 6.18 6.19 5.93 6.00 5,114,500 6.00
12-Dec-03 5.80 6.19 5.78 6.15 8,357,900 6.15
11-Dec-03 5.57 5.89 5.55 5.79 6,183,100 5.79
10-Dec-03 5.74 5.81 5.56 5.57 2,746,600 5.57
9-Dec-03 5.62 5.86 5.62 5.71 6,737,100 5.71
8-Dec-03 5.60 5.65 5.47 5.59 1,756,500 5.59
5-Dec-03 5.56 5.61 5.46 5.51 2,172,500 5.51
4-Dec-03 5.83 5.83 5.54 5.60 6,051,400 5.60
3-Dec-03 5.70 5.88 5.65 5.76 5,618,100 5.76
2-Dec-03 5.49 5.77 5.46 5.75 8,721,300 5.75
1-Dec-03 5.50 5.55 5.48 5.49 3,605,900 5.49
28-Nov-03 5.47 5.50 5.36 5.46 1,396,100 5.46
26-Nov-03 5.26 5.45 5.23 5.42 6,217,700 5.42
25-Nov-03 5.11 5.27 5.06 5.25 4,813,600 5.25
24-Nov-03 5.10 5.15 5.05 5.11 3,620,600 5.11
21-Nov-03 5.19 5.20 5.07 5.10 2,295,700 5.10
20-Nov-03 5.16 5.20 5.11 5.15 4,527,400 5.15
19-Nov-03 5.28 5.34 5.15 5.23 2,037,000 5.23
18-Nov-03 5.30 5.38 5.18 5.21 1,767,400 5.21
17-Nov-03 5.45 5.52 5.25 5.33 2,620,300 5.33
14-Nov-03 5.64 5.64 5.42 5.50 7,530,600 5.50
13-Nov-03 5.28 5.48 5.25 5.36 6,952,200 5.36
12-Nov-03 5.12 5.35 5.11 5.33 5,952,700 5.33
11-Nov-03 5.20 5.24 5.10 5.12 3,498,600 5.12
10-Nov-03 5.32 5.35 5.16 5.24 4,020,700 5.24
7-Nov-03 5.15 5.31 5.12 5.30 8,508,200 5.30
6-Nov-03 4.94 5.16 4.90 5.08 9,135,300 5.08
5-Nov-03 5.03 5.14 4.85 4.90 7,245,500 4.90
4-Nov-03 5.22 5.22 5.05 5.06 3,861,600 5.06
3-Nov-03 5.23 5.27 5.15 5.20 6,002,400 5.20
31-Oct-03 4.95 5.29 4.72 5.13 31,399,000 5.13
30-Oct-03 5.48 5.71 4.90 4.95 22,353,700 4.95
29-Oct-03 5.41 5.71 5.38 5.57 2,136,900 5.57
28-Oct-03 5.23 5.47 5.18 5.41 2,615,300 5.41
27-Oct-03 5.07 5.20 5.05 5.15 1,123,600 5.15
24-Oct-03 5.16 5.17 5.01 5.03 1,684,800 5.03
23-Oct-03 5.21 5.29 5.07 5.20 2,826,000 5.20
22-Oct-03 5.53 5.60 5.25 5.25 1,875,200 5.25
21-Oct-03 5.41 5.58 5.31 5.52 2,585,500 5.52
20-Oct-03 5.35 5.39 5.21 5.31 1,848,700 5.31
17-Oct-03 5.72 5.72 5.36 5.37 2,193,100 5.37
16-Oct-03 5.76 5.82 5.61 5.72 1,450,200 5.72
15-Oct-03 5.79 5.90 5.77 5.80 1,996,800 5.80
14-Oct-03 5.77 5.88 5.68 5.83 1,832,400 5.83
13-Oct-03 5.66 5.77 5.65 5.77 1,770,700 5.77
10-Oct-03 5.47 5.68 5.46 5.65 1,773,100 5.65
9-Oct-03 5.71 5.82 5.40 5.55 2,646,400 5.55
8-Oct-03 5.79 5.85 5.62 5.72 1,447,400 5.72
7-Oct-03 5.93 5.97 5.76 5.82 2,878,400 5.82
6-Oct-03 5.73 5.90 5.72 5.89 2,266,300 5.89
3-Oct-03 5.57 5.70 5.50 5.66 2,954,500 5.66
2-Oct-03 5.37 5.52 5.35 5.47 2,023,900 5.47
1-Oct-03 5.30 5.40 5.21 5.34 1,687,300 5.34
30-Sep-03 5.40 5.43 5.16 5.29 1,653,300 5.29
29-Sep-03 5.07 5.24 5.07 5.18 1,169,800 5.18
26-Sep-03 5.21 5.25 5.09 5.11 1,471,000 5.11
25-Sep-03 5.33 5.38 5.15 5.27 1,934,000 5.27
24-Sep-03 5.59 5.60 5.21 5.30 3,903,500 5.30
23-Sep-03 5.55 5.65 5.52 5.59 1,499,100 5.59
22-Sep-03 5.52 5.63 5.37 5.55 2,472,100 5.55
19-Sep-03 5.75 5.75 5.51 5.64 4,247,900 5.64
18-Sep-03 6.15 6.15 5.80 5.81 3,609,200 5.81
* Close price adjusted for dividends and splits.

First | Prev | Next | Last
Download To Spreadsheet

[kingofthehill]

Elan is being cleaned up to be sold.
guess is Wyeth. They know that the Alzheimers research is going to be worth billions and billions, because one of these days, Elan will come up with the cure, if they haven't already done so. Antegren is going to be worth billions for MS and I believe it will be cleared for Crohns because of the 12 week findings. Prialt is going to be a wonder drug for pain and the NDA for it will be filed very soon if it hasn't already. Then there is their nano technology that is going to be worth billions and billions more in the coming years. This is going to become the preferred drug delivery system for the entire world as the science progresses. And this dumb ass is asking what is there to sell.

[kingofthehill]

MORE FROM LEHMAN BROS. ON ELAN

[All the caps are Lehman's]

STOCK COMMENT – RECENT STRENGTH PARTLY FUELED BY SPECULATION OF EARLIER-THAN-EXPECTED ANTEGRAN NDA FILING FOR MS: While yesterday’s news is a positive for Elan, execution on bringing to market its key pipeline product Antegren remains critical to the company’s future growth. Our 1-OW investment rating primarily reflects reduced downside risk from a successful recovery plan. We continue to expect pipeline visibility to improve in 2004. Nevertheless, we also continue to see real product development risk and maintain our cautiously optimistic view, with the emphasis on “caution”. We believe that strength in Elan shares since our investment rating upgrade on November 14 reflects not just greater appreciation for the Elan story in general and the reduced risk profile that we have highlighted, but also some speculation on a potential earlier-than expected NDA filing for the multiple sclerosis(MS) indication for Antegran – which we, as well as Elan management and partner Biogen, do not expect until late 2004/early 2005, with
a 1H04 filing being very much a wildcard and highly unlikely. While more widespread speculation on the earlier-than-expected NDA filing for MS scenario may further fuel share price appreciation, we would not chase the stock on this expectation. As we stated, the next expected opportunity for pipeline assessment will likely be in 1Q04 with the release of ENACT II clinical results in Crohn’s – positive outcome may increase our confidence in Antegren’s regulatory and commercial outlook

[kingofthehill]

I AM SO GOOD TO YOU GUYS WHO ELSE GIVES YOU A WINNER LIKE

ELN ...high today $7.23 to close at 7.10

this stock is MASSIVE ..I AM MASSIVE ..... ELN ELN

THYE ALSO OWN 10% OF NGEN

[MEA_1956]

I AM SO GOOD TO YOU GUYS WHO ELSE GIVES YOU A WINNER LIKE

ELN ...high today $7.23 to close at 7.10

this stock is MASSIVE ..I AM MASSIVE ..... ELN ELN

THYE ALSO OWN 10% OF NGEN

Yes, I Was Just Wondering, Do you have a home page so all of us would be able to see if there was just a special sause you use or is there skill in your picks. Now me, I use the hit and miss method, missed E L N but road Sears to the top. I am in on N G E N, and today was just wounderful, do you have a third pick that you would like to share. If you like a slow ride you might consider B T N E . ob I spotted this one on pure luck and got in at $2.12 @ the first of Dec. It seems like some one picks up a nickel of this one every day, just to keep it climbing. ===>MEA

[kingofthehill]

do your own DD but i gotta say once the SEC clears ELN , and 2 new drugs they have this will move to the teens..also ELN OWNS about 10% of NGEN !! its not too late, i bought another 500 shares Friday at $7.10 ..i sold my NGEN last week ..i missed the last move in NGEN i have been very focused on this stock i may buy back into CDE and CAMD on dips ... but this ELN is a winner ...

if you want to know about this company try the http://finance.yahoo.com/q/mb?s=ELN

their are a few loose botls on the board thier but you can learn alot about where the company is headed

good luck to all in 2004

[kingofthehill]

AM I GOOD OR WHAT !!!!!!!!


ELN CLOSES AT $8.02 ON 24 MILLION SHARES !!!!!


DUE YOUR OWN DD

ELAN

[kingofthehill]

January 8, 2004

LENGTH: 434 words

HEADLINE: ELAN PASSES MILESTONE FOR NEW PAINKILLER

BYLINE: Liz Vaughan-Adams

BODY:


THE IRISH drug company Elan announced yesterday that its treatment for severe chronic pain had passed a key trial and would be on the market no later than the first quarter of next year.

The company, led by Kelly Martin, came close to insovlency last year and has been selling assets to bring its debts under control, It said its Prialt drug for patients with sever chronic pain had successfully completed Phase III trials.

The trial centred on patients who had not achieved pain relief with other therapies like, for example, intrathecally delivered (into the fluid in the spinal cord) morphine. At week three, the study - a double-blind, placebo-controlled study, showed that patients taking Prialt saw "statistically significant improvement".

Prialt is used in the treatment of severe chronic pain by patients suffering from illnesses such as cancer and Aids where other painkillers no longer work. It is administered intrathecally with an internal or external pump.

Elan said its analysis showed the treatment to be "safe, efficacious and well tolerated". It plans to file an amendment to its New Drug Application with the US Food and Drug Administration in the second quarter of this year.

It expects to bring the treatment - a drug it estimates could make revenues of $ 1.3bn to $ 1.5bn over its life - to market no later than the first quarter of next year.

Analysts at NCB Stockbrokers are forecasting $ 20m of sales of Prialt in 2005 and $ 50m the year after that and predict the drug's peak annual sales potential is around $ 150m.

Lars Ekman, Elan's president of research and development, said: "We are very encouraged by these definitive findings with Prialt and believe that this is significant news for patients suffering with severe chronic pain, many of whom are not now adequately treated." The FDA had previously issued an approvable letter for Prialt, asking for more information. This latest study, the company said, fulfilled that requirement.

The trial studied 220 patients with severe chronic pain to show the efficacy and safety of lower doses of Prialt. Elan said there were few serious side effects.

Elan cited data which shows there are around 2 million patients in the United States with chronic pain who fail to respond to existing treatments. Of those, around 300,00 might be considered suitable for intrathecal treatment like Prialt.

It is a fillip for the company that has been battling to get its debt under control. Last month, Elan sold its European sales and marketing business to the private equity group Apax Partners for $ 120m.

[kingofthehill]

just wanted to let the wallflowers here at mr. markets ....

13 million shares traded price range 7.80 -8.40

most of the day traded at 8.23 closed at 8.15

even the motley fool now likes the stock ... anyone else riding this train besides Me ???

OUR TAKE

Elan's Happy Pill?

The Motley Fool Take
Elan Corp.


By Jeff Hwang
January 8, 2004
Elan (NYSE: ELN) investors are feeling happy these days, as the company continues its rebound from potential disaster. Yesterday, the Irish drug developer accentuated those good vibes by reporting success in a Phase III trial for Prialt, a severe chronic pain treatment. On that news, Elan shares climbed 13% to $8.02 yesterday, and are up another 3% today.

The company said it expects to file an amendment to its New Drug Application (NDA) with the Federal Drug Administration in the second quarter of 2004. Elan also expects Prialt to be on the market by the first quarter of 2005.

This positive injection of good news comes at a good time; damage from the company's mass asset sales distracted from what was an otherwise positive earnings report. Those sales continued into last month, when Elan announced the $120 million sale of its European sales and marketing business.

But things look to be heading the other way. Revenues from continuing operations were up 31% last quarter, and Prialt should help build on that. Plus, Elan has a potential blockbuster waiting in its wings in Antegren, a Multiple Sclerosis treatment. Further, Fool Tom Jacobs expressed earlier that nabbing G. Kelly Martin from Merrill Lynch (NYSE: MER) was the right choice to help turnaround the company.

Even given the massive rebound in Elan's shares price, the stock may very well still be undervalued. However, as Fool Bill Mann would point out, investors should still be mindful that Elan still "has yet to receive a clean bill of health from the SEC."

Is Elan still undervalued? Is it worth the plunge? Debate it on the Elan discussion board – only at Fool.com.


Jeff Hwang can be reached at [email protected].

[kingofthehill]

Things are looking good for ELN

Elan's Former Neurex Product, Prialt, Hits Phase III Endpoint

By Cormac Sheridan



BioWorld International Correspondent
Elan Corp. plc aims to launch its non-opioid peptide-based analgesic Prialt "no later" than the first quarter of 2005, following news that the compound met its primary endpoint in a trial of 220 patients with severe chronic pain who had not obtained relief with other therapies.

The Dublin, Ireland-based pharmaceutical company hasn't released the results of the study, but plans to do so at an appropriate scientific meeting later this year. It said Wednesday that Prialt (ziconotide) achieved a statistically significant improvement at week three in the Visual Analogue Scale of Pain Intensity (VASPI) score.

Elan gained ownership of Prialt, a synthetic derivative of a peptide isolated from the venom of a Conus species of marine snail, when it acquired Neurex Inc. in 1998 in a stock swap valued at $741 million. The product, the first in its class, acts by blocking a neuron-specific N-type calcium channel. It is administered intrathecally, that is, into the cerebrospinal fluid surrounding the spinal cord, via a subcutaneously implanted pump supplied by Medtronic Inc., of Minneapolis.

The compound has a development history stretching back to the mid-1990s and was the subject of an FDA approvable letter in 2001 that asked for additional data. Since then, Elan has worked with the agency on the design of a study to evaluate its efficacy at a lower dosage and a slower titration rate than those used in two previous pivotal studies.

"The data from this study, then, represent the final element of this process and will be filed as an amendment to our new drug application with the FDA in the second quarter of this year," Lars Ekman, executive vice president and president of research and development at Elan, said in a conference call.

On the same call, CEO Kelly Martin said the product would be targeted at around 50 pain treatment centers in the U.S., saying, "We're quite familiar with them, and they're quite familiar with us." Some 39 of them were involved in the recent clinical study. The product will be aimed initially at three groups: cancer patients, AIDS patients with chronic pain and patients with neuropathic pain.

Martin said peak annual sales for Prialt could lie between $150 million and $250 million, based on a total potential market of 300,000 patients with chronic pain who are considered suitable candidates for intrathecal treatment.

"Three-thousand dollars to $4,000 per patient per month in this market space looks like the revenue opportunity," he said.

Only 30,000 to 50,000 patients have so far been fitted with the Medtronic device, although availability of Prialt could push that figure higher, Martin said.

"It's very hard to gauge how they're going to penetrate the market," said David Marshall, analyst at NCB Stockbrokers in Dublin. The company's most immediate target, he said, is likely to be that fraction of patients using intrathecal pumps who have become refractory to morphine or who suffer from respiratory side effects through its use.

"They may be able to capture that portion of the market quite quickly and have a slow ramp from there," he said.



Published January 14, 2004

[Michaelk005]

You have mentioned CDE may times in your posts. I am a big trader of the Gold mine, wondering your thoughts on the current dip. I went in at low $4s and am holding but I day trade this stock lots.
Inpute would be sweet, thanks

[casinoboy3]

ELN looking very nice. Nice pick. You think it's a good buying opportunity right now, or perhaps wait a little?

[kingofthehill]

there is still alot of upside ...anyone buying i before the SEC issue is resolved will be rewarded nicely Brokerage house will not cover a stock thats under sec. review ..this was a $60 stock i can see it being 15 by years end



it made a nice move today again $8.89 days high

http://www.wistv.com/global/story.asp?s=1608267&ClientType=Printable

Experimental pain killer for cancer patients derived from sea snail venom

(National) Jan. 20, 2004 - The venom of a sea snail could ease hard to treat pain in cancer and aids patients, according to new research published in the Journal of the American Medical Association.

Less than an inch long, small sea snails contain venom that paralyze their prey. A man made version of the potent venom has been shown to relieve severe pain, especially in cancer patients.

Georgia Robins Sadler, a cancer specialist at the University of California-San Diego, says, "For some patients it's absolutely unable to be relieved by pain medication, they think. That's an important difference. Most pain can be relieved."

Named Ziconotide, the drug works by coating the spinal column, similar to epidurals used in childbirth. Dr. Sadler says it allows patients to move without pain, "It's just like childbirth pain. You think about having your spinal cord area numb, so you don't have feeling from the waist down when delivering a child. This medication is delivered into the spinal cord area and helps numb some of the pain that's felt through the central nervous system."

A small battery operated pump implanted in the patient's back provides constant medication. Some side effects, like dizziness, were found in about 20 percent of patients. Risks that may be outweighed by the benefit of having another line of defense in fighting pain.

Elan, the makers of the Ziconotide, is now seeking FDA approval. With it they expect the drug to be available within the year.

posted 11:03am by Chris Rees

[kingofthehill]

24/01/04
Elan sell-off continues as positive drug trial results boost share prices

By Conor Keane - Business Correspondent
ROLL up, roll up, the great Elan sell-off continues and the more the company sells off the higher its share price goes.


Long-term Elan shareholders, now used to magical mystery tours along the high and lows of the share price bar chart, have ended yet another week in a twirl as the shares first rose and then slid again.





However, the underlying trend is positive. A year ago, on Friday, January 24, Elan shares closed at €3.44, a long way from the heady days of 2001 when the shares hit €65 but came crashing down as a result of a post-Enron accountancy problem. Yesterday, shares closed at €6.95, down 3.47% on the day, but well up on the year low of €2.05.

The first respite shareholders in Elan got this year was .on January 8, when shares in Elan surged 11% on good news for painkiller Prialt.

Elan revealed its recent Phase III trial for Prialt had met its primary end-point in patients with severe chronic pain who had not achieved pain relief with other therapies. The firm said it expects to bring the treatment to market no later than the first quarter of 2005.

Not exactly the blockbuster drug the company needs, as potential sales are not in the major league, but crucially, it was positive news that at last Elan was back in the game.

This week, Elan announced sell-off deals, worth around 90 million in cash, in order to further reduce their colossal debts.

Elan chief executive Kelly Martin said: "These transactions are consistent with our strategy of focusing our resources on our core therapeutic focus areas, developing our pipeline, and bringing innovative science to patients. They represent further success in our commitment to reposition Elan for the future."

Elan was rated a buy by Goodbody stockbrokers yesterday morning.